HCV / Hepatitis

Successful HCV treatment with DAAs was associated with reduced risks of CKD, stroke, major adverse cardiac events, and neurocognitive disorders.

This week, the FDA expanded Moderna’s RSV vaccine to younger at-risk adults, Merck’s Enflonsia received approval to protect infants from RSV, HHS Secretary RFK Jr replaced the CDC’s ACIP, and more.

The antiviral, glecaprevir/pibrentasvir (Mavyet), is the first and only oral 8-week pangenotypic treatment approved for people with acute or chronic hepatitis C. The approval supports global clinical guidelines to advance testing and treatment of HCV regardless of chronicity and supports public health goals for disease elimination.

Hydronidone demonstrated significant efficacy in liver fibrosis regression in CHB patients, meeting the primary endpoint in a phase 3 trial. The company plans to file regulatory applications in China and the US, aiming to expand the therapy's indications.

Therapeutic vaccines GS-2829 and GS-6779 demonstrate immune responses and strong safety profile, showing potential to contribute to global hepatitis B elimination efforts.

Multinational real-world analysis underscores the effectiveness of sofosbuvir/velpatasvir (SOF/VEL) across diverse populations and highlights the need for timely treatment initiation to improve patient outcomes.

The company detailed its preliminary 24-week post–end-of-treatment data for its tobevibart and elebsiran combination, which is being studied for chronic hepatitis B.

Anu Osinusi, MD provides insights on the findings of Gilead’s investigational therapy from its phase 3 MYR301 study, which are being reported at the ongoing European Association for the Study of the Liver (EASL) Congress 2025.

Anu Osinusi, MD, discusses the findings examining bulevirtide as a standalone therapy and in combination with pegylated interferon alpha.

LA County confirms 165 cases since 2024 with 29 in 2025 alone, including individuals without known risk factors.

Atea Pharmaceuticals' investigational combination treatment of bemnifosbuvir and ruzasvir showed these results after an 8-week treatment regimen.

Rising tick-borne illnesses due to warmer winters, strong hepatitis E vaccine efficacy during an outbreak, emerging fungal threats and resistance, and more.

The Hecolin hepatitis E virus vaccine was delivered with a reduced 2-dose schedule to people living in a refugee camp to try to reduce an outbreak.

World Malaria day stories, update on measles outbreak, coronavirus antivirals showing strong results in testing, and more this week.

Q&A with Ben Burwitz, PhD, on the significance of the new hepatitis B virus (HBV)-susceptible primate model and its potential to advance hepatitis B research and therapeutic development.

Atea Pharmaceuticals will present the full clinical study at the upcoming EASL Congress in May.

While 254 million affected globally with HBV, the disease remains endemic in Nigeria due to imperfect vaccination efficacy and limited coverage

Sarah Rowan, MD, on minimal laboratory testing, Hepatitis B screening flexibility, peer navigation, and state‑specific strategies to overcome outreach and reimbursement hurdles

Sarah Rowan, MD, says tailored models within syringe service programs can overcome barriers and improve cure rates in underserved populations.

Universal hepatitis C screening updates have influenced testing numbers, and resulted in a gradual increase for all women with a pronounced increase in pregnant women.

With valid phase 2 results, hydronidone could pave the way for first antifibrotic treatment in chronic liver disease.

Yael David, PhD, discusses how cccDNA nucleosome positioning drives HBV transcription and how CBL137 disrupts this process to block infection.

Precision BioSciences received the designation for its gene editing therapy, PBGENE-HBV, developed to eliminate the root cause of chronic hepatitis B virus (HBV).

National Youth HIV & AIDS Awareness Day emphasizes the urgent need for culturally responsive initiatives, discoveries in hepatitis B and C, FDA fast tracks H5N1 vaccine development, and more.

Although there have been decreases in newly reported chronic hepatitis C cases across many demographics, the need to get people screened and given therapy in the same visit remains vital.